Table 1.
Demographic characteristics
| Characteristic | hypoAlb patients (n = 79) |
NhypoAlb patients (n = 79) |
|---|---|---|
| Age, years | 54.9 | 55.1 |
| Dialysis vintage, months | 34.7 | 45.3 |
| Incident HD patients,a % | 15.2% | 3.8% |
| Male, % | 53.2% | 53.2% |
| Race, % | ||
| Black | 35.4% | 35.4% |
| White | 62.0% | 62.0% |
| Other | 2.6% | 2.6% |
| Hispanic/Latino, % | 11.4% | 26.6% |
| BMI, kg/m2 | 31.4 | 31.3 |
| Baseline PB not recorded, % | 34.2% | 26.6% |
| Baseline PB recorded, % | ||
| Calcium acetate (CaAc) | 26.6% | 24.1% |
| Sevelamer (Sev) | 36.7% | 48.1% |
| Lanthanum carbonate | 1.3% | 1.3% |
| Switch between Sev/CaAc | 1.3% | 0.0% |
| Primary cause of ESRD, % | ||
| Diabetes | 54.4% | 40.5% |
| Hypertension | 21.5% | 34.2% |
| Glomerulonephritis | 7.6% | 8.9% |
| Polycystic kidney | 0.0% | 1.3% |
| Other/ unknown | 16.4% | 15.2% |
| Comorbid conditions, % | ||
| Diabetes | 63.3% | 63.3% |
| Congestive heart failure | 21.5% | 20.3% |
Summary statistics are presented as mean or percentage
Abbreviations: BMI body mass index, ESRD end-stage renal disease, HD hemodialysis, hypoAlb hypoalbuminemic, NhypoAlb non-hypoalbuminemic, PB phosphate binder, SO sucroferric oxyhydroxide
aPatients with dialysis vintage < 120 days prior to SO initiation